Jeff Bird, Managing Director at Bluebird Ventures, Palo Alto, California, United States — verified investor profile. See contact routes.
Jeffrey Bird, MD, PhD, is the founder and Managing Director of Bluebird Ventures, an early-stage life sciences firm in Palo Alto, California, where he leverages over 20 years of venture investing experience and a prior 12-year executive tenure at Gilead Sciences. His investment thesis focuses exclusively on early-stage life science companies developing therapeutics, diagnostics, genomics, gene therapy, RNA therapeutics, and medical devices, primarily within the United States. While specific check sizes and lead/follow behavior are not publicly detailed, the firm frequently participates in repeat rounds to support companies from early clinical development through expansion stages. Notable portfolio companies include Procyrion, Forty Seven, Portola Pharmaceuticals, and Verinata Health, a diagnostics company Bird previously led as CEO before its sale to Illumina. Bird has served on the boards of numerous public companies, including Forty Seven, Portola, and Horizon Pharmaceuticals, drawing on deep operational and commercialization experience to guide founding teams. There is no publicly available distinctive point of view or published writing attribu
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Palo Alto.
Investors like Jeff Bird · Full investor directory · Investor access · Company funding database